TROG Cancer Research
Members Login   CQMS Login  

Closed lymphoma trials

Trials closed to recruitment

TROG 05.02 (MALT Lymphoma) - the main aim of this study was to test the effectiveness of radiotherapy for marginal zone lymphoma that has developed outside the stomach.

Primary sponsor: TROG
Collaborating groups: Australasian Leukaemia & Lymphoma Group (ALLG); Princess Margaret Hospital, Toronto, Canada


TROG 03.03 (HDNLHL4) - in this study, radiotherapy was given to all the areas known to be affected by lymphoma (other than bone marrow) with the aims of assessing the ability of radiotherapy to reduce the risk of relapse following transplantation, and carefully evaluating the side effects of adding radiotherapy to transplantation.

Primary sponsor: Australasian Leukaemia & Lymphoma Group (ALLG)
Collaborating group: TROG


TROG 01.02 - this clinical research study looked at a new combination of chemotherapy drugs (Idarubicin and Methotrexate) followed by a lower dose of radiotherapy in participants with Primary Central Nervous System Lymphoma (PCNSL). The main purpose of this study was to assess the effectiveness of this treatment and its effect on the ability of patients to perform normal daily functions.

Primary sponsor: TROG
Collaborating group: Australasian Leukaemia & Lymphoma Group (ALLG); Amgen (Neupogen)


TROG 99.03 - this study compared standard therapy (radiotherapy) and investigational therapy (radiotherapy plus chemotherapy) to see if adding chemotherapy extends the time until the lymphoma progresses in those patients that will not be cured.

Primary sponsor: TROG
Collaborating groups: Australasian Leukaemia & Lymphoma Group (ALLG); Princess Margaret Hospital, Toronto


Completed trials

TROG 99.04 - A Prospective, Non-Randomised Study of Chemotherapy and Radiotherapy for Osteolymphoma (OL)

TROG 99.01 - An ANZLG / TROG Prospective Study of Limited Chemotherapy and Involved Field Radiotherapy for Patients With Clinical Stage I-II Hodgkin’s Disease

TROG 92.01 - A Phase II Study of Intravenous Methotrexate and Cranial Irradiation in the Treatment of Primary Central Nervous System Lymphoma (PCNSL)

We are thankful to our 14,000 patients who have participated in our research. Please continue the generous support.